GlassScriptPhysician profile
Donald Nicol
NPI 1053367284
$2,253.78
in general payments reported to CMS, 2019-2025
12 companies · $171 in 2025
The $171 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $305 · 2021: $420 · 2022: $566 · 2023: $241 · 2024: $206 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $617.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $489.90 | 2019-2024 | Breztri, Airsupra |
| Lilly USA, LLC | $396.13 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $378.49 | 2020-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $218.77 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $198.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $158.44 | 2022-2023 | |
| Amgen INC. | $137.85 | 2024-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.88 | 2019-2025 | Jardiance |
| Pfizer INC. | $64.25 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $44.12 | 2025 | Zoryve |
| Galt Pharmaceuticals, LLC | $36.08 | 2023 | Orphengesic Forte, Oravig |
| Teva Pharmaceuticals USA, INC. | $11.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Nicol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.